Who has been buying KM Pharmaceutical stock?

5 distinct insiders have filed 235 disclosed insider purchases in KM Pharmaceutical (225430), most recently on 2026-07-06. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does KM Pharmaceutical have?

KM Pharmaceutical has 235 buy-side and 0 sell-side disclosures on record, covering ₩109M ($76K) in total reported value, spanning 2024-03-05 to 2026-07-06.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

KM Pharmaceutical 225430

Company

케이엠제약KM Pharmaceutical

Insiders

Buys

235

Total Value

₩109M ($76K)

Avg Return

+46.62%

Last Filing

2026-07-06

KM Pharmaceutical (225430) has 235 disclosed insider purchases and 0 disclosed disposals on record, filed by 5 distinct insiders. Together those filings cover ₩109M ($76K) in reported transaction value. The earliest filing StockDrifts holds for KM Pharmaceutical is dated 2024-03-05; the most recent is 2026-07-06. Across these filings the average return since disclosure is +46.62%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-09-16	BUY	Market Buy	황민영 Minyoung Hwang	Managing Director	11.3K	₩698	+0.0%	₩7M ($5K)
2026-09-15	BUY	Market Buy	황민영 Minyoung Hwang	Managing Director	2.0K	₩698	+0.0%	₩1M ($931)
2026-09-14	BUY	Market Buy	강일모 Kang Il-mo	Chairman	5.5K	₩698	+0.0%	₩3M ($2K)
2026-09-14	BUY	Market Buy	강일모 Kang Il-mo	Chairman	544	₩698	+0.0%	₩296K ($206)
2026-09-14	BUY	Market Buy	황민영 Minyoung Hwang	Managing Director	47.6K	₩698	+0.0%	₩25M ($17K)
2026-09-14	BUY	Market Buy	강일모 Kang Il-mo	Chairman	3.5K	₩698	+0.0%	₩2M ($1K)
2026-09-14	BUY	Market Buy	강일모 Kang Il-mo	Chairman	5.2K	₩698	+0.0%	₩3M ($2K)
2026-09-14	BUY	Market Buy	강일모 Kang Il-mo	Chairman	5.5K	₩698	+0.0%	₩3M ($2K)
2026-09-14	BUY	Market Buy	강일모 Kang Il-mo	Chairman	5.0K	₩698	+0.0%	₩3M ($2K)
2026-09-11	BUY	Market Buy	강일모 Kang Il-mo	Chairman	322	₩682	+2.4%	₩195K ($136)
2026-09-11	BUY	Market Buy	강일모 Kang Il-mo	Chairman	9.5K	₩682	+2.4%	₩6M ($4K)
2026-09-11	BUY	Market Buy	강일모 Kang Il-mo	Chairman	2.0K	₩682	+2.4%	₩1M ($840)
2026-07-30	BUY	Market Buy	강일모 Kang Il-mo	Chairman	1.3K	₩1,755	+2.6%	₩2M ($1K)
2026-07-25	BUY	제3자배정유상증자	BAIK BRIAN SEUNG WON(백승원) BAIK BRIAN SEUNG WON	CEO	908.3K	₩1,469	+22.5%	₩1000M ($694K)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	12	₩1,445	+24.6%	₩17K ($12)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	31	₩1,445	+24.6%	₩46K ($32)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	3	₩1,445	+24.6%	₩4K ($3)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	123	₩1,445	+24.6%	₩178K ($124)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	206	₩1,445	+24.6%	₩298K ($207)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	3	₩1,445	+24.6%	₩4K ($3)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	5	₩1,445	+24.6%	₩7K ($5)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	171	₩1,445	+24.6%	₩248K ($172)
2026-07-24	BUY	Market Buy	강일모 Kang Il-mo	Chairman	6	₩1,445	+24.6%	₩9K ($6)
2026-07-22	BUY	Market Buy	강일모 Kang Il-mo	Chairman	999	₩1,407	+27.9%	₩1M ($1K)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	48	₩1,387	+3.8%	₩59K ($41)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	15	₩1,387	+3.8%	₩18K ($13)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	20	₩1,387	+3.8%	₩25K ($17)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	37	₩1,387	+3.8%	₩46K ($32)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	13	₩1,387	+3.8%	₩16K ($11)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	64	₩1,387	+3.8%	₩78K ($54)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	5	₩1,387	+3.8%	₩6K ($4)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	151	₩1,387	+3.8%	₩186K ($130)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	177	₩1,387	+3.8%	₩219K ($152)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	46	₩1,387	+3.8%	₩57K ($40)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	177	₩1,387	+3.8%	₩219K ($152)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	9	₩1,387	+3.8%	₩11K ($8)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	44	₩1,387	+3.8%	₩55K ($38)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	155	₩1,387	+3.8%	₩193K ($134)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	3	₩1,387	+3.8%	₩4K ($3)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	46	₩1,387	+3.8%	₩58K ($40)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	68	₩1,387	+3.8%	₩85K ($59)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	14	₩1,387	+3.8%	₩17K ($12)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	206	₩1,387	+3.8%	₩250K ($174)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	216	₩1,387	+3.8%	₩262K ($182)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	31	₩1,387	+3.8%	₩38K ($26)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	50	₩1,387	+3.8%	₩61K ($42)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	2	₩1,387	+3.8%	₩2K ($2)
2026-07-15	BUY	Market Buy	강일모 Kang Il-mo	Chairman	53	₩1,387	+3.8%	₩65K ($45)
2026-07-06	BUY	Market Buy	강일모 Kang Il-mo	Chairman	193	₩1,536	-13.3%	₩296K ($206)
2026-07-06	BUY	Market Buy	강일모 Kang Il-mo	Chairman	31	₩1,536	-13.3%	₩48K ($33)

Showing the 50 most recent of 200 filings.

Frequently asked questions

Who has been buying KM Pharmaceutical stock?: 5 distinct insiders have filed 235 disclosed insider purchases in KM Pharmaceutical (225430), most recently on 2026-07-06. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does KM Pharmaceutical have?: KM Pharmaceutical has 235 buy-side and 0 sell-side disclosures on record, covering ₩109M ($76K) in total reported value, spanning 2024-03-05 to 2026-07-06.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.